9 completed, 2 terminated, 1 active not recruiting. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 9, Terminated 2, Active not recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow XRP6258: new trials by email Literature Review of XRP6258 trials Research Report on XRP6258
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 37 | 2015-08-13 | 2026-09-15 |
| Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Cabazitaxel (XRP6258) - Malignant Solid Tumor - Malignant Nervous System Neoplasm | Phase 1 / Phase 2 | Completed | Sanofi | 39 | 2013-02-01 | 2016-08-12 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
| Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Mitoxantrone, Prednisone - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | Rahul Aggarwal | 25 | 2012-06-01 | 2017-07-21 |
| Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide - Prostate Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 20 | 2011-09-22 | 2025-05-15 |
| Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer Cabazitaxel (XRP6258), prednisolone - Prostate Cancer | Phase 1 | Completed | Sanofi | 48 | 2011-01-01 | 2015-01-07 |
| Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment Cabazitaxel (XRP6258) - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 56 | 2010-05-01 | 2015-07-21 |
| Effect of Cabazitaxel on the QTc Interval in Cancer Patients Cabazitaxel (XRP6258) - Neoplasms, Malignant | Phase 1 | Completed | Sanofi | 45 | 2010-03-01 | 2011-12-16 |
| Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor cabazitaxel, gemcitabine - Neoplasms, Malignant | Phase 1 / Phase 2 | Terminated | Sanofi | 19 | 2009-11-01 | 2013-09-11 |
| A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer cabazitaxel (XRP6258) - Solid Cancer | Phase 1 | Completed | Sanofi | 76 | 2009-06-01 | 2013-05-16 |
| A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors Cabazitaxel (XRP6258) - Advanced Solid Tumor | Phase 1 | Completed | Sanofi | 42 | 1999-10-01 | 2012-12-24 |
Prostatic Neoplasms (5) · Neoplasms (3) · Neoplasm Metastasis (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1)
Sanofi (7) · OHSU Knight Cancer Institute (2) · M.D. Anderson Cancer Center (1) · Rahul Aggarwal (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (10) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Japan (1) · Netherlands (1) · Spain (1) · Sweden (1)
Julie N Graff (1) · Lara Davis, MD (1) · Paul Corn (1) · Rahul Aggarwal, MD (1) · Robert Den, MD (1)
PMID 24099585, PMID 25117475, PMID 25809824, PMID 31515154, PMID 39863139
2009 (1), P30CA016672 (1)